U.S. Gas Utilities Stock News

Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond declining multiple sclerosis and Spinraza sales with newer drugs such as Leqembi, Skyclarys, Qalsody, and Zurzuvae. More recently, Biogen’s agreement to acquire RayThera Inc. for US$1.00 billion and the FDA’s Breakthrough Therapy designation for Salanersen have highlighted management’s effort to refresh the pipeline just as competition...

Earlier in June 2026, C3.ai board member Jim H. Snabe took a leave of absence to serve as Special Envoy to the European Commission for Industrial Artificial Intelligence, stepping back from his board vote and advisory duties while remaining expected to return after his envoy role ends. His appointment places a long-serving C3.ai insider at the center of European industrial AI policymaking, potentially giving the company early insight into evolving regulations and enterprise requirements...

Recent share performance and what it tells you Avnet (AVT) has moved sharply in recent periods, with the stock up 75.1% year to date and 67.9% over the past year. The past month shows a relatively flat return near 0.6%. See our latest analysis for Avnet. Recent trading has been choppy for Avnet, with the share price down 4.9% on the day and 5.6% over the past week. However, the 90 day share price return of 47.4% and 1 year total shareholder return of 67.9% still point to strong underlying...

Why Seadrill’s latest credit amendment matters for SDRL stock Seadrill (NYSE:SDRL) has amended its Senior Secured Revolving Credit Agreement, increasing revolving borrowing commitments, extending the facility’s maturity to 2031, and adjusting covenants to allow greater financial and operational flexibility. This move, alongside a recent extension of the company’s share repurchase plan to December 31, 2026, gives investors fresh information about Seadrill’s current approach to liquidity,...

Steel Dynamics (STLD) stock has drawn fresh attention after recent trading performance, with the share price at $245.49 and mixed short term returns that contrast with stronger outcomes over the past year. See our latest analysis for Steel Dynamics. Recent trading has cooled, with the share price down 5.64% over the past month. However, Steel Dynamics still shows strong momentum when looking at the 42.91% 90 day share price return and 89.63% 1 year total shareholder return. If you are...

With global data sending mixed signals, from resilient Chinese manufacturing and shifting bond yields to uneven consumer confidence, many investors are looking for companies where analysts still expect clear earnings growth and balance sheet strength. That is where the Healthy high growth potential screener comes in, filtering for stocks that combine analyst-backed earnings growth expectations over the next 3 years with solid financial footing. In this article, you will see 3 stocks from this...

LyondellBasell Industries (LYB) has moved into focus after receiving a Zacks Rank #1 rating, a shift driven by higher earnings estimates, growth indicators and a dividend yield that stands out in its sector. See our latest analysis for LyondellBasell Industries. Despite the positive earnings revisions and Zacks Rank upgrade, LyondellBasell Industries has seen its share price fall 16.38% over the past month and 32.35% over the past quarter, while the 1 year total shareholder return of 2.33%...

Ligand Pharmaceuticals recently completed a US$625,000,000 Rule 144A offering of zero-coupon, senior unsecured convertible notes due September 15, 2031, following a broader US$1,000,000,000 shelf registration for equity and related securities. A key aspect of this financing is Ligand’s plan to pair the convertible notes with call spreads and share repurchases, aiming to manage potential dilution while preserving flexibility for acquisitions such as the previously announced XOMA Royalty...

Recently, commentary on Genuine Parts highlighted that its annual sales growth, same-store sales over the past two years, and operating margin have all lagged key industry peers, raising fresh questions about its competitive performance. This combination of softer sales metrics and below-average profitability has sharpened investor focus on whether Genuine Parts can reliably generate incremental demand and sustain earnings quality in a tougher operating backdrop. We’ll now explore how...

Lamb Weston Holdings has recently faced reports of flat organic revenue, declining earnings per share, and is restructuring its European operations by closing a Netherlands production facility to improve efficiency. These moves highlight how the frozen potato producer is reworking its footprint and cost base in response to weaker demand across key markets. Next, we will examine how Lamb Weston’s European restructuring and efficiency focus may alter the existing investment narrative for the...

Earlier in June 2026, Redwire Corporation received preliminary court approval for a proposed settlement of shareholder derivative actions, which includes adopting multi‑year corporate governance reforms and paying US$912,500 in legal fees funded by insurers, pending final approval at a July 30, 2026 hearing. The settlement process highlights how shareholder litigation can drive concrete governance changes that Redwire’s own board acknowledges as a substantial benefit to the company and its...

Teledyne MEMS recently expanded its Edmonton manufacturing operations with Government of Alberta support and was chosen by CMC Microsystems’ FABrIC initiative as the advanced MEMS manufacturing partner for Noze Inc. and Sheba Microsystems Inc. to help commercialize healthcare and automotive imaging technologies in Canada. These moves deepen Teledyne’s role in Canada’s semiconductor ecosystem, aligning its advanced MEMS capabilities with government-backed innovation and higher-value...

Jabil (JBL) is back in focus after strong third quarter results, higher full year revenue guidance of about US$35b, and a new AI focused manufacturing alliance with Adani Enterprises in India. See our latest analysis for Jabil. Despite a recent pullback, including a 1-day share price return of down 4.28% and a 7-day share price return of down 3.57%, Jabil’s momentum over longer periods remains strong. The company has a 90-day share price return of 44.90% and a 1-year total shareholder return...

AI Infrastructure Stocks sit at the crossroads of real world assets and digital demand, just as many economies are reworking trade, inflation and interest rate expectations. While headlines range from China’s industrial data to shifting bond yields and inflation readings across the US, Europe and emerging markets, one constant is that AI systems still rely on power, cooling and connectivity that must be built and maintained. This screener focuses on companies turning that physical backbone...

Ituran Location and Control (NasdaqGS:ITRN) has drawn renewed investor attention after a recent share price pullback, with the stock down 7% over the past week and 7% over the past month. See our latest analysis for Ituran Location and Control. Despite the recent 7% pullback over the past week, Ituran Location and Control still reflects strong momentum, with the 90 day share price return at 26.66% and the 1 year total shareholder return at 71.34%. If you are weighing Ituran Location and...

Pfizer (PFE) is in focus after investors were hit with mixed oncology news, a planned CFO transition, and fresh questions around its pipeline, all set against the backdrop of patent expirations and restructuring efforts. See our latest analysis for Pfizer. At a share price of $24.29, Pfizer has seen weaker momentum in recent months, with a 30 day share price return of 7.22% and a 90 day share price return of 12.53% despite oncology updates, legal clarity around Paxlovid, and a confirmed...

BioMarin Pharmaceutical (BMRN) is back in focus after new VOXZOGO and BMN 333 data at ENDO 2026, adding fresh context to a stock that recently reacted to mixed quarterly results and updated guidance. See our latest analysis for BioMarin Pharmaceutical. Alongside the ENDO 2026 update and a recent quarter that was mixed but included higher guidance, BioMarin Pharmaceutical’s share price shows short-term momentum building, with a 7.88% seven-day share price return and a 7.68% 90-day share price...

Viking Holdings (VIK) has taken delivery of two new German-built river ships, the Viking Annar and Viking Fjolvar, aimed at expanding European itineraries on the Rhine, Main, Danube and Seine. See our latest analysis for Viking Holdings. Against this backdrop of fleet expansion, Viking Holdings has also seen strong positive momentum in its stock, with a 90 day share price return of 50.85% and a 1 year total shareholder return of 95.86%, pointing to investors reassessing both growth prospects...

Douglas Dynamics (PLOW) is back on investors’ radar after four consecutive earnings beats, with earnings per share growing faster than revenue and free cash flow giving the company more room for new initiatives and shareholder returns. See our latest analysis for Douglas Dynamics. Investors have taken notice of Douglas Dynamics’ recent earnings surprises, and the stock’s momentum reflects that, with a 30 day share price return of 20.97% feeding into a 63.35% year to date share price return...

Bio-Rad Laboratories (BIO) has drawn investor attention after recent share moves, with the stock up 0.8% on the day and 6.5% over the past week, despite a decline over the past month. See our latest analysis for Bio-Rad Laboratories. Set against a 1 year total shareholder return of 23.3% but a 5 year total shareholder return that is down 54.9%, Bio-Rad Laboratories’ recent 6.5% 7 day share price gain after a weaker 30 day share price return suggests short term momentum is improving, while...

Tango Therapeutics (TNGX) recently appointed biopharmaceutical executive Robert Azelby to its Board of Directors, as the company advances investigational PRMT5 inhibitor vopimetostat toward potential late stage development in pancreatic cancer. See our latest analysis for Tango Therapeutics. Tango Therapeutics' share price has recently shown strong momentum, with a 30 day share price return of 43.18% and a year to date share price return of 252.41%. The 1 year total shareholder return is very...

Massive rollovers from 401(k)s into IRAs are quietly reshaping where retirement dollars sit and who earns fees on them. With nearly $682 billion moving in 2023 and much more projected over the next several years, financial firms tied to retirement advice, wealth management, and IRA servicing are directly in the spotlight. This article looks at how that rollover surge, looser oversight on solicitation, and growing retiree demographics intersect, then walks through 3 stocks from our Retirement...

Analyst interest builds around ESCO Technologies after strong year-to-date run ESCO Technologies (ESE) has drawn fresh attention after a Zacks report highlighted its 75.6% year-to-date return and a favorable Rank #2 rating, with analysts pointing to improving earnings estimates as a key driver. See our latest analysis for ESCO Technologies. At a share price of $339.88, ESCO Technologies has had a strong run, with the 30 day share price return of 16.44% feeding into a year to date share price...

If you are wondering whether Centrus Energy is starting to look more interesting at current levels, the key question is how its market price compares with a grounded view of value. The stock last closed at US$165.52, with the share price down 13.5% over the past week, 9.3% over the past month and 39.3% year to date, although the three year return sits at a very large gain of about 5x. Recent coverage has focused on Centrus Energy's role in the nuclear fuel supply chain and its position in...